KEYMED BIO-B News

KEYMED BIO-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Apr 24 04:37 ET

KEYMED BIO-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Apr 24 04:35 ET

KEYMED BIO-B: FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING

Apr 24 04:34 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT UPDATE ON THE LICENSE AGREEMENT WITH ASTRAZENECA ON CMG901 (AZD0901)

Apr 11 20:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 8 04:52 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 6 03:38 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 6 03:39 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE 2022 RESTRICTED SHARE UNIT SCHEME

Jan 22 05:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Jan 2 05:52 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF CM310 FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS ACHIEVED PRIMARY ENDPOINTS

Dec 26, 2023 19:15 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADULTS ACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Dec 6, 2023 23:21 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023

Dec 4, 2023 03:45 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT THE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OF CMG901 AT THE ASCO PLENARY SERIES BY WAY OF ORAL PRESENTATION

Nov 7, 2023 19:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023

Nov 6, 2023 03:32 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT CM310 PHASE III CLINICAL TRIAL TOPLINE DATA ACCEPTED FOR POSTER SESSION AT THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS 2023

Oct 11, 2023 04:30 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023

Oct 4, 2023 04:34 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023

Sep 4, 2023 09:34 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2023

Aug 2, 2023 04:31 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023

Jul 3, 2023 04:40 ET

KEYMED BIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Jun 27, 2023 09:04 ET